Dexa Medica

Executive Summary

Dexa Medica, one of Indonesia's largest pharmaceutical companies, manufactures a broad portfolio of generic, branded, and herbal medicines, with core capabilities in API production, solid dosage manufacturing, and biomolecular discovery. Founded in 1969 and headquartered in Palembang, the company serves therapeutic areas including antibiotics, cardiovascular, anti-inflammatory, and general medicine, focusing on affordable, high-quality medicines to improve public health. With over 1,000 employees and a commercial-stage presence, Dexa Medica is well-positioned in Indonesia's growing pharmaceutical market, driven by increasing healthcare demand and government initiatives for local drug production. The company's integrated API manufacturing and biomolecular research provide competitive advantages in cost control and innovation. As Indonesia pushes for pharmaceutical self-sufficiency, Dexa Medica is likely to benefit from preferential procurement policies. Its herbal medicine segment also aligns with the global trend toward natural remedies, offering expansion opportunities. However, as a private company with limited public disclosures, near-term visibility is moderate. Key growth drivers include potential commercialization of novel drug delivery systems, expansion of herbal product lines, and export partnerships in Southeast Asia.

Upcoming Catalysts (preview)

• H2 2026Commercialization of novel biomolecular drug delivery system55% success
• Q1 2027Regulatory approval for new herbal medicine product line70% success
• Q4 2026Export partnership for generic APIs in ASEAN markets60% success